Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: Role of insulin resistance

Gut

Volumn 53, Issue 7, 2004, Pages 1020-1023

  Donati, G ^a   Stagni, B ^a   Piscaglia, F ^a   Venturoli, N ^b   Morselli Labate, A M ^a   Rasciti, L ^a   Bolondi, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Regional Center for Transplantation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; GLUCOSE; INSULIN; LIVER ENZYME;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; FATTY LIVER; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOTHESIS; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTIVARIATE ANALYSIS; NONHUMAN; PATIENT; PLASMA; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SAMPLE;

ADULT; AGED; ALANINE TRANSAMINASE; BLOOD GLUCOSE; BODY MASS INDEX; FATTY LIVER; FEMALE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED;

EID: 3042521502     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.027086     Document Type: Article

References (28)

1. Younossi Z, Diehl A, Ong J. Non alcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002;35:746-52.
2. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-17.
3. Falck-Ytter Y, Younossi Z, Marchesini G, et al. Clinical features and natural history of non alcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
4. Teli M, James O, Burt A, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714-19.
5. Powell E, Cookesley W, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
6. Braillon A, Capron J, Herve M, et al. Liver in obesity. Gut 1985;26:133-9.
7. James O, Day P. Nonalcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998;29:495-501.
8. Kemmer N, McKinney K, Xiao S, et al. High prevalence of non alcoholic steatohepatitis among Mexican females with type II diabetes mellitus. Gastro 2001;120:A117.
9. Czaja A, Carpenter H, Santrach P, et al. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998;29:198-206.
10. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
11. Sanyal J, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastro 2001;120:1138-92.
12. Marchesini G, Brizi M, Morselli-Labate A, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.
13. Lee J, Rhee P, Lee J, et al. Role of hyperinsulinemia and glucose intolerance in the pathogenesis of nonalcoholic fatty liver in patients with normal body weight. Korean J Intern Med 1998;13:12-14.
14. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4.
15. Fong D, Nehra V, Lindor K, et al. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000;32:3-10.
16. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7.
17. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990;39:167-74.
18. Laakso M, Edelman S, Brechtel G, et al. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990;85:1844-52.
19. Landsberg L. Insulin resistance and hypertension. Clin Exp Hypertens 1999;21:885-94.
20. Steinberg H, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilatation. J Clin Invest 1997;100:1230-9.
21. Berson A, Beco VD, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastro 1998;114:764-74.
22. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-54.
23. Matthews D, Hosker J, Rudenski A, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
24. Saverymuttu S, Joseph A, Maxwell J. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. BMJ 1986;292:13-15.
25. Joseph A, Saverymuttu S, Al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clinical Radiol 1991;43:26-31.
26. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow up in an Italian population. Dig Dis Sci 1997;42:1428-32.
27. Vozarova B, Stefan N, Lindsay R, et al. High alanine aminotransferases is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:1889-95.
28. Kashiwabara H, Inaba M, Maruno Y, et al. Insulin levels during fasting and the glucose tolerance test and Homa's index predict subsequent development of hypertension. J Hypertens 2000;18:83-8.